Lantheus Holdings Inc(LNTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 24.15 | EPS (ttm) | 4.14 | Insider Own | 3.52% | Shs Outstand | 65.3M | Perf Week | - |
| Market Cap | 6.52B | Forward P/E | 15.6 | EPS next Y | 18.28% | Insider Trans | - | Shs Float | 63.0M | Perf Month | 0.18% |
| Enterprise Value | 6.56B | PEG | 1.74 | EPS next Q | 1.26 | Inst Own | 114.61% | Short Float | 6.01% | Perf Quarter | -2.65% |
| Income | 0.28B | P/S | 4.19 | EPS this Y | -10.95% | Inst Trans | 0.28% | Short Ratio | 2.71 | Perf Half Y | 18.8% |
| Sales | 1.56B | P/B | 4.97 | EPS next 5Y | 8.96% | ROA | 12.15% | Short Interest | 3.78M | Perf YTD | 50.14% |
| Book/sh | 20.1 | P/C | 11 | EPS past 3/5Y | 104.81% - | ROE | 22.21% | 52W High | -10.67% ($111.86) | Perf Year | 78.24% |
| Cash/sh | 9.09 | P/FCF | 16.82 | Sales past 3/5Y | 18.13% 35.35% | ROIC | 14.22% | 52W Low | 99.22% ($50.15) | Perf 3Y | 52.09% |
| Dividend Est. | - | EV/EBITDA | 16.76 | EPS Y/Y TTM | 7.38% | Gross Margin | 60.14% | Volatility(W/M) | 0.41% 0.37% | Perf 5Y | 337.48% |
| Dividend TTM | - | EV/Sales | 4.21 | Sales Y/Y TTM | 2.35% | Oper. Margin | 19.45% | ATR (14) | 0.45 | Perf 10Y | 1048.51% |
| Dividend Ex-Date | - | Quick Ratio | 2.89 | EPS Q/Q | -0.79% | Profit Margin | 17.69% | RSI (14) | 46.17 | Recom | 2.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.06 | Sales Q/Q | 2.68% | SMA20 | -0.05% ($99.97) | Beta | 0.01 | Target Price | $106.06 |
| Payout | - | Debt/Eq | 0.48 | Earnings | 2026/8/6 | SMA50 | -0.35% ($100.27) | Rel Volume | 0.31 | Prev Close | $99.8 |
| Employees | 1193 | LT Debt/Eq | 0.48 | EPS/Sales Surpr. | 18.9% 6.87% | SMA200 | 10.16% ($90.7) | Avg Volume(3M) | 1.40M | Price | $99.92 |
| IPO | 2015/6/25 | Option/Short | Yes/Yes | Trades | 4895 | Volume | 431,739 | Change | 0.12% |
🔬 A U.S. healthcare company that develops and sells radiopharmaceuticals for diagnosis and treatment, as well as imaging contrast agents. With a core focus on radiopharmaceuticals used in prostate cancer diagnostic imaging and ultrasound contrast agents, the company is also expanding into therapeutic radiopharmaceuticals, making it a pharmaceutical stock whose performance is closely tied to revenue from its key products and pipeline.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded less than usual. That is 31% of its average volume.
LNTH makes money exceptionally well
Of every $100 in sales, $19.45 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -10.9% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,415. Peers typically go for $2,109. It is about in line with its own 4-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +337.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 114.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #12 of 83 in the industry
Based on market cap of $7B.
ALKS#10 Alkermes plc $7B PER 115.4 
AMRX#11 Amneal Pharmaceuticals Inc $7B PER 43.9 LNTH#12 Lantheus Holdings Inc $7B PER 24.1 
HIMS#13 Hims & Hers Health Inc $6B PER - 
KNSA#14 Kiniksa Pharmaceuticals International Plc $6B PER 74.2 
FAQ
What kind of company is LNTH?
LNTH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LNTH?
The market cap of LNTH is approximately $6.5B, ranking 1,156 within its sector.
What is the P/E ratio of LNTH?
LNTH has a P/E ratio of approximately 24.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LNTH?
LNTH has recorded a 52-week high of $111.86 and a low of $50.15.
